Several studies indicated that neither the tissue polypeptide specific antigen nor combined positive score of PD-L1 expression was associated with pathologic response.42,43,60,61 However, based on data from the study by Yang et al,62 compared with the non-pCR group, the pCR group had significantly higher levels of PD-L1 and tumor mutation burden before treatment. The gene discussed is CD274; the disease is neoplasm.